Colorado’s first-in-the-nation workers’ compensation program evaluation reimbursing medical cannabis may represent more than an isolated state experiment. As federal officials move toward rescheduling cannabis from Schedule I to Schedule III, the trial run offers an early look at how medical cannabis could eventually be integrated into traditional healthcare reimbursement systems.
Today, medical cannabis remains almost entirely a cash expense. Patients—even those with physician recommendations—typically pay out of pocket because federal prohibition prevents most insurers from treating cannabis like other prescription medications.
Rescheduling would not automatically require insurers to cover medical cannabis. However, by recognizing cannabis as a medication with accepted medical use under federal law, it would remove one of the largest legal barriers preventing insurers from developing reimbursement models. It would also expand opportunities for clinical research that insurers often rely on when making coverage decisions.
That shift could ultimately allow medical cannabis to follow a pathway more similar to other prescription therapies, with physician oversight, standardized dosing, insurance reimbursement and broader patient access. And a Colorado study published this spring gives a window into what that could look like, specifically for injured workers.
A peer-reviewed study published in the Journal of Occupational and Environmental Medicine documented what researchers
